Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCENESSE + NB-UVB in Generalized Vitiligo
NCT06109649Phase 3Active, not recruiting
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- Peptides, Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of Afamelanotide in generalized vitiligo, sponsored by Clinuvel Pharmaceuticals. Started Oct 2023; status: active, not recruiting.
02
Drugs
Afamelanotide
03
Conditions
generalized vitiligo
Beyond the preview
Go deeper on NCT06109649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06109649.